Dendritic cell-based in vitro assays for vaccine immunogenicity

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 9, 2012, Pages 1323-1325

  Vandebriel, Rob J ^a   Hoefnagel, Marcel H N ^b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

Author keywords

3R; Adjuvant; Dendritic cells; Immunogenicity; In vitro assay; Maturation; Vaccine

Indexed keywords

ALPHA INTERFERON; ANTIGEN POLYRIBOSYL RIBITOL PHOSPHATE; BACTERIAL PROTEIN; BCG VACCINE; BETA INTERFERON; CD38 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HLA DR ANTIGEN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 5; INTERLEUKIN 6; LIVE VACCINE; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

ADAPTIVE IMMUNITY; CD4+ CD154+ GAMMA INTERFERON+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; NONHUMAN; NOTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

DENDRITIC CELLS; HUMANS; VACCINES;

EID: 84866998187     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21350     Document Type: Note

References (14)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52; PMID:9521319; http://dx.doi.org/10.1038/32588.
2. Larsson K, Lindstedt M, Borrebaeck CA. Functional and transcriptional profiling of MUTZ-3, a myeloid cell line acting as a model for dendritic cells. Immunology 2006; 117:156-66; PMID:16423051; http://dx.doi.org/10.1111/j.1365- 2567.2005.02274.x.
3. Hoefnagel MH, Vermeulen JP, Scheper RJ, Vandebriel RJ. Response of MUTZ-3 dendritic cells to the different components of the Haemophilus influenzae type B conjugate vaccine: towards an in vitro assay for vaccine immunogenicity. Vaccine 2011; 29:5114-21; PMID:21624423; http://dx.doi.org/10.1016/j.vaccine. 2011.05.050.
4. Kim KD, Choi SC, Noh YW, Kim JW, Paik SG, Yang Y, et al. Impaired responses of leukemic dendritic cells derived from a human myeloid cell line to LPS stimulation. Exp Mol Med 2006; 38:72-84; PMID:16520555.
5. Rasaiyaah J, Noursadeghi M, Kellam P, Chain B. Transcriptional and functional defects of dendritic cells derived from the MUTZ-3 leukaemia line. Immunology 2009; 127:429-41; PMID:19538250; http://dx.doi.org/10.1111/j.1365- 2567.2008.03018.x.
6. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006; 203:413-24; PMID:16461338; http://dx.doi.org/10.1084/jem.20051720.
7. Bodewes R, Geelhoed-Mieras MM, Heldens JG, Glover J, Lambrecht BN, Fouchier RA, et al. The novel adjuvant CoVaccineHT increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitro. Vaccine 2009; 27:6833-9; PMID:19772942; http://dx.doi.org/10.1016/j.vaccine.2009.09.015.
8. Giacomini E, Remoli ME, Gafa V, Pardini M, Fattorini L, Coccia EM. IFN-beta improves BCG immunogenicity by acting on DC maturation. J Leukoc Biol 2009; 85:462-8; PMID:19056860; http://dx.doi.org/10.1189/jlb.0908583.
9. Goriely S, Molle C, Nguyen M, Albarani V, Haddou NO, Lin R, et al. Interferon regulatory factor 3 is involved in Toll-like receptor 4 (TLR4)- and TLR3-induced IL-12p35 gene activation. Blood 2006; 107:1078-84; PMID:16219795; http://dx.doi.org/10.1182/blood-2005-06-2416.
10. Egger M, Jürets A, Wallner M, Briza P, Ruzek S, Hainzl S, et al. Assessing protein immunogenicity with a dendritic cell line-derived endolysosomal degradome. PLoS ONE 2011; 6:e17278; PMID:21359181; http://dx.doi.org/10.1371/journal.pone.0017278.
11. Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 2005; 307:1630-4; PMID:15761154; http://dx.doi.org/10.1126/science. 1108003.
12. Delamarre L, Couture R, Mellman I, Trombetta ES. Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J Exp Med 2006; 203:2049-55; PMID:16908625; http://dx.doi.org/10.1084/jem.20052442.
13. Jiang X, Shen C, Rey-Ladino J, Yu H, Brunham RC. Characterization of murine dendritic cell line JAWS II and primary bone marrow-derived dendritic cells in Chlamydia muridarum antigen presentation and induction of protective immunity. Infect Immun 2008; 76:2392-401; PMID:18362126; http://dx.doi.org/10. 1128/IAI.01584-07.
14. Moser JM, Sassano ER, Leistritz C, Eatrides JM, Phogat S, Koff W, et al. Optimization of a dendritic cell-based assay for the in vitro priming of naïve human CD4+ T cells. J Immunol Methods 2010; 353:8-19; PMID:19925804; http://dx.doi.org/10.1016/j.jim.2009.11.006.